九强生物 (300406.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	1.4B	1.4B	1.7B	1.7B	1.5B
Cost of Revenue	279.1M	279.9M	356.7M	441.3M	383.9M
Gross Profit	1.1B	1.1B	1.3B	1.3B	1.1B
Operating Expenses
R&D Expense	179.3M	181.7M	188.5M	162.9M	137.2M
SG&A Expense	—	—	—	—	—
General & Admin Expense	133.9M	137.5M	143.5M	127.0M	109.0M
Selling & Marketing Expense	271.5M	271.3M	314.2M	364.1M	348.4M
Other Expenses	—	—	—	—	—
Total Operating Expenses	645.5M	649.9M	699.4M	711.1M	655.6M
Cost and Expenses	924.6M	929.8M	1.1B	1.2B	1.0B
Operating Income (EBIT)	261.9M	236.0M	624.1M	593.9M	455.5M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	262.2M	236.3M	620.7M	593.6M	449.4M
Income Tax Expense	49.6M	45.7M	83.9M	71.5M	54.9M
Bottom Line
Net Income	212.2M	189.9M	538.3M	523.7M	389.1M
Earnings from Cont. Ops	212.6M	190.5M	536.8M	522.1M	394.5M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	212.2M	189.9M	538.3M	523.7M	389.1M
Per Share
Basic EPS	CN¥0.36	CN¥0.32	CN¥0.93	CN¥0.90	CN¥0.67
Diluted EPS	CN¥0.36	CN¥0.32	CN¥0.90	CN¥0.88	CN¥0.67
Revenue Per Share	CN¥2.34	CN¥2.28	CN¥2.87	CN¥2.99	CN¥2.60
Shares
Basic Shares Outstanding	586.7M	593.4M	578.8M	581.9M	580.7M
Diluted Shares Outstanding	586.7M	593.4M	578.8M	581.9M	580.7M
Profitability Metrics
EBITDA	—	306.6M	694.6M	648.6M	509.4M
D&A	—	70.6M	70.6M	54.7M	53.9M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026